Peptide-based Cardiovascular Therapeutics Market-Drivers
Increasing prevalence of cardiovascular diseases globally is expected to drive the peptide-based cardiovascular therapeutics market growth during the forecast period. For instance, according to the World Health Organization 2017 report, around 17.9 million deaths were recorded from cardiovascular diseases worldwide in 2016.
Furthermore, research and development and clinical trials of new peptide-based therapeutics is expected to drive growth of the peptide-based cardiovascular therapeutics market during the forecast period. For instance, according to the National Center for Biotechnology Information’s 2015 report, there is an increasing interest in peptide formation in pharmaceutical research and development (R&D) and around 140 peptide-based therapeutics are being evaluated in clinical trials.
Peptide-based Cardiovascular Therapeutics Market-Restraints
Rapid metabolism of peptide drug is expected to restrain the peptide-based cardiovascular therapeutics market growth during the forecast period. For instance, according to National Center for Biotechnology Information’s 2015 report, natural peptides have poor absorption, distribution, metabolism, and excretion (ADME) properties with rapid clearance, short half-life, low permeability, and low solubility.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients